# US 2023/0406934 A1 · Ungulate-derived polyclonal immunoglobulin specific for pd-li and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406934 A1
- Document ID: US20230406934A1
- Status: Published application
- Kind: A1
- Application number: 18/036,567
- Filed: 2021-11-12
- Published: 2023-12-21
- Earliest claimed: 2020-11-13
- Assignees: Sab, LLC
- Applicants: Sab, LLC
- Inventors: Christoph L. BAUSCH; Hua Wu; Kristi A. EGLAND; Eddie J. SULLIVAN
- Web page: https://patentgrep.com/patent/US20230406934A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/06: from serum
- A61K 2039/505: {comprising antibodies}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are human polyclonal immunoglobulin products specific for Programmed Death-Ligand 1 (PD-L1) for use in treating or preventing cancer. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.

## Claims

### Claim 1

An ungulate-derived polyclonal human immunoglobulin composition, comprising a population of human immunoglobulins, wherein the population of human immunoglobulins specifically binds Programmed Death-Ligand 1 (PD-L1).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is produced by immunizing a transgenic ungulate with an antigenic fragment of PD-L1.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the antigenic fragment of PD-L1 is a PD-L1 extracellular domain.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the antigenic fragment comprises, consists of, or consists essentially of SEQ ID NO: 15 or a variant thereof.

### Claim 5 (depends on 3, 4)

The composition of claim 3 or 4, wherein the antigenic fragment shares at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 15 or a fragment thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the population of human immunoglobulins binds MC38-hPD-L1 cells with at least as high affinity, or higher affinity than atezolizumab.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the population of human immunoglobulins binds to a non-small cell lung cancer cell, optionally one or more of H292, H460, H1975, HCC827, and H1299 cells.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the population of human immunoglobulins exhibit complement-dependent-cytotoxicity (CDC) activity, optionally at an IC5o of about 0.72 μg/mL or less.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the population of human immunoglobulins inhibits tumor cell growth in vivo.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the population of human immunoglobulins exhibit antibody-dependent cellular toxicity (ADCC) activity.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1 to 10, wherein the population of human immunoglobulins block PD-L1 from binding to the PD-1 receptor.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the population of human immunoglobulins blocks the PD-1 signaling pathway.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the population of human immunoglobulin enhances effector cell function, such as natural killer cells.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the population of human immunoglobulins has an avidity for PD-L1 of at least 0.1 1/sec, at least 0.01 1/sec, at least 0.001 1/sec at least 0.0001 1/sec, or at least 0.00001 1/sec.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the population of human immunoglobulins has an avidity for PD-L1 of 0.1 to 0.01 1/sec, 0.01 to 0.001 1/sec, 0.001 to 0.0001 1/sec, or 0.0001 to 0.00001 1/sec.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The composition of any one of claims 1 to 15, wherein, the population of human immunoglobulin composition is substantially similar to ATCC Deposit No. PTA-127159 or wherein population of human immunoglobulins has an avidity for PD-L1 at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, or at least 120% as great as that of ATCC Deposit No. PTA-127159.

### Claim 17

A method of making polyclonal human immunoglobulin specific for Programmed Death-Ligand 1 (PD-L1), comprising administering an antigenic fragment of PD-L1, or a polynucleotide encoding the antigenic fragment, to a transgenic ungulate,
wherein the transgenic ungulate comprises a genome comprising a human immunoglobulin locus or an artificial chromosome comprising a human immunoglobulin locus, and wherein the transgenic ungulate produces a population of human immunoglobulins that specifically binds PD-L1.

### Claim 18 (depends on 17)

The method of claim 17, comprising administering the antigenic fragment or polynucleotide encoding the antigenic fragment 3, 4, 5, or more times.

### Claim 19 (depends on 17, 18)

The method of claim 17 or claim 18, comprising collecting serum or plasma from the transgenic ungulate.

### Claim 20 (depends on 17, 18, 19)

The method of any one of claims 17 to 19, wherein the serum or plasma comprises a population of fully human immunoglobulins.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17 to 20, wherein the antigenic fragment of PD-L1 is a PD-L1 extracellular domain.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antigenic fragment comprises, consists of, or consists essentially of SEQ ID NO: 15 or a variant thereof.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein the antigenic fragment shares at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 15 or a fragment thereof.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 17 to 23, wherein the population of human immunoglobulins binds MC38-hPD-L1 cells with at least as high affinity, or higher affinity than atezolizumab.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 17 to 24, wherein the population of human immunoglobulins binds to a non-small cell lung cancer cell, optionally one or more of H292, H460, H1975, HCC827, and H1299 cells.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 17 to 25, wherein the population of human immunoglobulins exhibit complement-dependent-cytotoxicity (CDC) activity, optionally at an IC5o of about 0.72 μg/mL or less.

### Claim 27 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 17 to 26, wherein the population of human immunoglobulins inhibits tumor cell growth in vivo.

### Claim 28 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 17 to 27, wherein the antigenic fragment is administering in a pharmaceutical composition comprising Montanide ISA-206 and/or Quil A.

### Claim 29 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 17 to 28, comprising:
a) administering a polynucleotide encoding the antigenic fragment of PD-L1;
b) administering a polynucleotide encoding the antigenic fragment of PD-L1, three to four weeks later;
c) administering the antigenic fragment of PD-L1, four weeks later
d) administering the antigenic fragment of PD-L1, four weeks later; and
e) administering the antigenic fragment of PD-L1, four weeks later.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 17 to 29, comprising purifying the human immunoglobulin to produce a composition according to any one of claims 1 to 16.

### Claim 31 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 17 to 30, wherein the population of human immunoglobulins exhibit antibody-dependent cellular toxicity (ADCC) activity.

### Claim 32 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 17 to 31, wherein the population of human immunoglobulins block PD-L1 from binding to PD-1.

### Claim 33 (depends on 32)

The method of claim 32, wherein the population of human immunoglobulins blocks the PD-1 signaling pathway.

### Claim 34 (depends on 33)

The method of claim 33, wherein the population of human immunoglobulin enhances effector cell function, optionally natural killer cells.

### Claim 35 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 17 to 34, wherein the population of human immunoglobulins has an avidity for PD-L1 of at least 0.1 1/sec, at least 0.01 1/sec, at least 0.001 1/sec at least 0.0001 1/sec, or at least 0.00001 1/sec.

### Claim 36 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 17 to 35, wherein the population of human immunoglobulins has an avidity for PD-L1 of 0.1 to 0.01 1/sec, 0.01 to 0.001 1/sec, 0.001 to 0.0001 1/sec, or 0.0001 to 0.00001 1/sec.

### Claim 37 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 17 to 36, wherein, the population of human immunoglobulin composition is substantially similar to ATCC Deposit No. PTA-127159 or wherein population of human immunoglobulins has an avidity for PD-L1 at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, or at least 120% as great as that of ATCC Deposit No. PTA-127159.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition, comprising the composition of any one of claims 1 to 16 and optionally one or more pharmaceutically acceptable excipients.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 38)

A method of treating or preventing cancer in a subject in need thereof, comprising administering an effective amount of the composition of any one of claims 1 to 16 or the pharmaceutical composition of claim 38 to the subject.

### Claim 40

A rabbit immunoglobulin composition, comprising a population of rabbit immunoglobulins, wherein the population rabbit immunoglobulins specifically binds Programmed Death-Ligand 1 (PD-L1).

### Claim 41 (depends on 40)

The composition of claim 40, wherein the composition is produced by immunizing a rabbit with an antigenic fragment of PD-L1.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the antigenic fragment of PD-L1 is a PD-L1 extracellular domain.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the antigenic fragment comprises, consists of, or consists essentially of SEQ ID NO: 15 or a variant thereof.

### Claim 44 (depends on 42, 43)

The composition of claim 42 or 43, wherein the antigenic fragment shares at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 15 or a fragment thereof.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The composition of any one of claims 40 to 44, wherein the population of rabbit immunoglobulins binds MC38-hPD-L1 cells with at least as high affinity, or higher affinity than atezolizumab.

### Claim 46 (depends on 40, 41, 42, 43, 44, 45)

The composition of any one of claims 40 to 45, wherein the population of rabbit immunoglobulins binds to a non-small cell lung cancer cell, optionally one or more of H292, H460, H1975, HCC827, and H1299 cells.

### Claim 47 (depends on 40, 41, 42, 43, 44, 45)

The composition of any one of claims 40 to 45, wherein the population of rabbit immunoglobulins exhibit complement-dependent-cytotoxicity (CDC) activity, optionally at an IC5o of about 0.72 μg/mL or less.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45)

The composition of any one of claims 40 to 45, wherein the population of rabbit immunoglobulins inhibits tumor cell growth in vivo.

### Claim 49 (depends on 40, 41, 42, 43, 44, 45)

The composition of any one of claims 40 to 45, wherein the population of rabbit immunoglobulins exhibit antibody-dependent cellular toxicity (ADCC) activity.

### Claim 50 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The composition of any one of claims 40 to 49, wherein the population of rabbit immunoglobulins block PD-L1 from binding to the PD-1 receptor.

### Claim 51 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The composition of claim 40 to 50, wherein the population of rabbit immunoglobulins blocks the PD-1 signaling pathway.

### Claim 52 (depends on 50)

The composition of claim 50, wherein the population of rabbit immunoglobulin enhances effector cell function, such as natural killer cells.

### Claim 53 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 40 to 52, wherein the population of rabbit immunoglobulins has an avidity for PD-L1 of at least 0.1 1/sec, at least 0.01 1/sec, at least 0.001 1/sec at least 0.0001 1/sec, or at least 0.00001 1/sec.

### Claim 54 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 40 to 52, wherein the population of rabbit immunoglobulins has an avidity for PD-L1 of 0.1 to 0.01 1/sec, 0.01 to 0.001 1/sec, or 0.0001 to 0.00001 I/sec.

### Claim 55 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The composition of any one of claims 40 to 54, wherein, the population of rabbit immunoglobulin composition is substantially similar to ATCC Deposit No. PTA-127159 or wherein population of rabbit immunoglobulins has an avidity for PD-L1 at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, or at least 120% that of ATCC Deposit No. PTA-127159.

### Claim 56

A method of making polyclonal rabbit immunoglobulin specific for Programmed Death-Ligand 1 (PD-L1), comprising administering an antigenic fragment of PD-L1, or a polynucleotide encoding the antigenic fragment, to a rabbit,
wherein the rabbit produces a population of rabbit immunoglobulins that specifically binds PD-L1.

### Claim 57 (depends on 56)

The method of claim 56, comprising administering the antigenic fragment or polynucleotide encoding the antigenic fragment 3, 4, 5, or more times.

### Claim 58 (depends on 56, 57)

The method of claim 56 or claim 57, comprising collecting serum or plasma from the rabbit.

### Claim 59 (depends on 56, 57, 58)

The method of any one of claims 56 to 58, wherein the serum or plasma comprises a population of fully rabbit immunoglobulins.

### Claim 60 (depends on 56, 57, 58, 59)

The method of any one of claims 56 to 59, wherein the antigenic fragment of PD-L1 is a PD-L1 extracellular domain.

### Claim 61 (depends on 60)

The method of claim 60, wherein the antigenic fragment comprises, consists of, or consists essentially of SEQ ID NO: 15, or a variant thereof.

### Claim 62 (depends on 60, 61)

The method of claim 60 or claim 61, wherein the antigenic fragment shares at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 15 or a fragment thereof.

### Claim 63 (depends on 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 56 to 62, wherein the population of rabbit immunoglobulins binds MC38-hPD-L1 cells with at least as high affinity, or higher affinity than atezolizumab.

### Claim 64 (depends on 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 56 to 63, wherein the population of rabbit immunoglobulins binds to a non-small cell lung cancer cell, optionally one or more of H292, H460, H1975, HCC827, and H1299 cells.

### Claim 65 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 56 to 64, wherein the population of rabbit immunoglobulins exhibit complement-dependent-cytotoxicity (CDC) activity, optionally at an IC50 of about 0.72 pg/mL or less.

### Claim 66 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 56 to 65, wherein the population of rabbit immunoglobulins inhibits tumor cell growth in vivo.

### Claim 67 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 56 to 66, wherein the antigenic fragment is administering in a pharmaceutical composition comprising Montanide ISA-206 and/or Quil A.

### Claim 68 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 56 to 67, comprising:
a) administering a polynucleotide encoding the antigenic fragment of PD-L1;
b) administering a polynucleotide encoding the antigenic fragment of PD-L1, three to four weeks later;
c) administering the antigenic fragment of PD-L1, four weeks later
d) administering the antigenic fragment of PD-L1, four weeks later; and
e) administering the antigenic fragment of PD-L1, four weeks later.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 56 to 68, comprising purifying the rabbit immunoglobulin to produce a composition according to any one of claims 1 to 16.

### Claim 70 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 56 to 69, wherein the population of rabbit immunoglobulins exhibit antibody-dependent cellular toxicity (ADCC) activity.

### Claim 71 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 56 to 70, wherein the population of rabbit immunoglobulins block PD-L1 from binding to PD-1.

### Claim 72 (depends on 71)

The method of claim 71, wherein the population of rabbit immunoglobulins blocks the PD-1 signaling pathway.

### Claim 73 (depends on 72)

The method of claim 72, wherein the population of rabbit immunoglobulin enhances effector cell function, optionally natural killer cells.

### Claim 74 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 56 to 73, wherein the population of rabbit immunoglobulins has an avidity for PD-L1 of at least 0.1 1/sec, at least 0.01 1/sec, at least 0.001 1/sec at least 0.0001 1/sec, or at least 0.00001 1/sec.

### Claim 75 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 56 to 73, wherein the population of rabbit immunoglobulins has an avidity for PD-L1 of 0.1 to 0.01 1/sec, 0.01 to 0.001 1/sec, 0.001 to 0.0001 1/sec, or 0.0001 to 0.00001 1/sec.

### Claim 76 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 56 to 73, wherein, the population of rabbit immunoglobulin composition is substantially similar to ATCC Deposit No. PTA-127159 or wherein population of rabbit immunoglobulins has an avidity for PD-L1 at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, or at least 120% as great as that of ATCC Deposit No. PTA-127159.

### Claim 77 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A pharmaceutical composition, comprising the composition of any one of claims 40 to 55 and optionally one or more pharmaceutically acceptable excipients.

### Claim 78 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 77)

A method of treating or preventing cancer in a subject in need thereof, comprising administering an effective amount of the composition of any one of claims 40 to 55 or the pharmaceutical composition of claim 77 to the subject.
